Format

Send to

Choose Destination
See comment in PubMed Commons below
Thyroid. 2011 May;21(5):487-92. doi: 10.1089/thy.2011.2121. Epub 2011 Apr 10.

Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier.

Author information

1
Divisions of Endocrinology and Oncology, The Ohio State University College of Medicine and Arthur G. James Comprehensive Cancer Center, Columbus, Ohio, USA. matthew.ringel@osumc.edu

Abstract

BACKGROUND:

Metastatic dormancy, or the ability of cancer cells to survive but not progress in metastatic environments, is now recognized to be a common occurrence in cancer.

SUMMARY:

From a clinical perspective, this phenomenon is common in metastatic well-differentiated thyroid cancer, whereby patients often present with distant metastases that remain stable for years after removal of the primary tumor and subsequent treatment. Experimental data suggest that metastases can develop throughout the life of a cancer and that progression in the distant environment depends on the biology of the cancer cells that metastasize as well as that of the various microenvironments they encounter. A firm understanding of how thyroid cancer cell progression is regulated in different metastatic environments is necessary to devise effective therapies targeting progressive metastatic thyroid cancer.

CONCLUSION:

In this review, current models of metastatic progression and factors that regulate late-stage metastatic progression that are particularly relevant for thyroid cancer are discussed.

PMID:
21476892
PMCID:
PMC3092721
DOI:
10.1089/thy.2011.2121
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Mary Ann Liebert, Inc. Icon for PubMed Central
    Loading ...
    Support Center